Dissecting the Genetic Heterogeneity of Gallbladder Stone Formation

ABSTRACT

Gallstone disease affects almost 20% of individuals in Westernized countries. As its incidence in the developing countries is rising considerably, currently, it is the second most common gastroenterological condition worldwide. Gallstone formation is driven by an interaction between genetic and environmental risk factors. Previous studies have demonstrated that the genetic background accounts for ~25% of the total disease risk. Linkage and case-control studies of candidate genes and recent genome-wide studies have identified multiple lithogenic genes, in particular the hepatocanalicular cholesterol transporter ABCG5/G8 and the bilirubin conjugating enzyme UGT1A1, as major genetic determinants of gallstones in humans. In this review, we summarize the recent findings related to the genetics of cholelithiasis, update the “inventory” of human lithogenic genes, and relate the genetic studies to the pathobiologic background of the disease. In closing, future applications of genetic testing for gallstone carriers and asymptomatic family members are addressed.

KEYWORDS

Candidate gene - cholelithiasis - genome-wide association study - individualized medicine - multifactorial disease

REFERENCES

• 1 Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease.  Lancet. 2006;  368 (9531) 230-239
• 2 Völzke H, Baumeister S E, Alte D et al.. Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence.  Digestion. 2005;  71 (2) 97-105
• 3 Palasciano G, Portincasa P, Vinciguerra V et al.. Gallstone prevalence and gallbladder volume in children and adolescents: an epidemiological ultrasonographic survey and relationship to body mass index.  Am J Gastroenterol. 1989;  84 (11) 1378-1382
• 4 Lammert F, Sauerbruch T. Mechanisms of disease: the genetic epidemiology of gallbladder stones.  Nat Clin Pract Gastroenterol Hepatol. 2005;  2 (9) 423-433
• 5 Attili A F, Capocaccia R, Carulli N Multicenter Italian Study on Epidemiology of Cholelithiasis et al. Factors associated with gallstone disease in the MICOL experience.  Hepatology. 1997;  26 (4) 809-818
• 6 Barbara L, Sama C, Morselli Labate A M et al.. A population study on the prevalence of gallstone disease: the Sirmione Study.  Hepatology. 1987;  7 (5) 913-917
• 7 Gibney E J. Asymptomatic gallstones.  Br J Surg. 1990;  77 (4) 368-372
• 8 Festi D, Sottili S, Colecchia A et al.. Clinical manifestations of gallstone disease: evidence from the multicenter Italian study on cholelithiasis (MICOL).  Hepatology. 1999;  30 (4) 839-846
• 9 Lammert F, Neubrand M W, Bittner R Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten et al. S3-guidelines for diagnosis and treatment of gallstones.  Z Gastroenterol. 2007;  45 (9) 971-1001
• 10 Tomida S, Abei M, Yamaguchi T et al.. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis.  Hepatology. 1999;  30 (1) 6-13
• 11 Friedman G D, Raviola C A, Fireman B. Prognosis of gallstones with mild or no symptoms: 25 years of follow-up in a health maintenance organization.  J Clin Epidemiol. 1989;  42 (2) 127-136
• 12 Thistle J L, Cleary P A, Lachin J M, Tyor M P, Hersh T. The natural history of cholelithiasis: the National Cooperative Gallstone Study.  Ann Intern Med. 1984;  101 (2) 171-175
• 13 Liver Disease Subcommittee of the Digestive Disease Interagency Coordinating Committee .Gallbladder and biliary disease. In: National Institutes of Health, ed. Action Plan for Liver Disease Research. Bethesda, MD: National Institutes of Health; 2004: 145-150
• 14 Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall H U. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs.  Hepatology. 2005;  41 (5) 1138-1143
• 15 Wittenburg H, Lammert F. Genetic predisposition to gallbladder stones.  Semin Liver Dis. 2007;  27 (1) 109-121
• 16 Krawczyk M, Müllenbach R, Weber S N, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases.  Nat Rev Gastroenterol Hepatol. 2010;  7 (12) 669-681
• 17 Schafmayer C, Hartleb J, Tepel J et al.. Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany.  BMC Gastroenterol. 2006;  6 36
• 18 Wang H H, Portincasa P, Afdhal N H, Wang D Q. Lith genes and genetic analysis of cholesterol gallstone formation.  Gastroenterol Clin North Am. 2010;  39 (2) 185-207, vii–viii
• 19 Lammert F, Miquel J F. Gallstone disease: from genes to evidence-based therapy.  J Hepatol. 2008;  48 (Suppl 1) S124-S135
• 20 Small D M. Role of ABC transporters in secretion of cholesterol from liver into bile.  Proc Natl Acad Sci U S A. 2003;  100 (1) 4-6
• 21 Dixon P H, van Mil S W, Chambers J et al.. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy.  Gut. 2009;  58 (4) 537-544
• 22 Rosmorduc O, Hermelin B, Boelle P Y, Parc R, Taboury J, Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults.  Gastroenterology. 2003;  125 (2) 452-459
• 23 Krawczyk M, Lüjohann D, Schirin-Sokhan R et al.. A 1254: Serum phytosterols and cholesterol precursors levels indicate increased cholesterol output and biosynthesis as independent predictive risk factors of cholesterol gallstones.  Hepatology. 2010;  52 (Suppl 4) 929A
• 24 Acalovschi M, Ciocan A, Mostean O et al.. Are plasma lipid levels related to ABCG5/ABCG8 polymorphisms? A preliminary study in siblings with gallstones.  Eur J Intern Med. 2006;  17 (7) 490-494
• 25 Gylling H, Hallikainen M, Pihlajamäki J et al.. Polymorphisms in the ABCG5 and ABCG8 genes associated with cholesterol absorption and insulin sensitivity.  J Lipid Res. 2004;  45 (9) 1660-1665
• 26 Cahalane M J, Neubrand M W, Carey M C. Physical-chemical pathogenesis of pigment gallstones.  Semin Liver Dis. 1988;  8 (4) 317-328
• 27 Brink M A, Slors J F, Keulemans Y C et al.. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease.  Gastroenterology. 1999;  116 (6) 1420-1427
• 28 Johnson A D, Kavousi M, Smith A V et al.. Genome-wide association meta-analysis for total serum bilirubin levels.  Hum Mol Genet. 2009;  18 (14) 2700-2710
• 29 Buch S, Schafmayer C, Völzke H et al.. Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition.  Gastroenterology. 2010;  139 (6) 1942-1951, e2
• 30 Lin J P, Schwaiger J P, Cupples L A et al.. Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels—the Framingham Heart Study.  Atherosclerosis. 2009;  206 (1) 228-233
• 31 Sanna S, Busonero F, Maschio A et al.. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia.  Hum Mol Genet. 2009;  18 (14) 2711-2718
• 32 Wang D Q, Afdhal N H. Gallstone disease. In: Feldman M, Brandt L, Friedman L, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 9th ed. Philadelphia: Elsevier Saunders; 2010: 1089-1120
• 33 Huang Y C, Zhang X W, Yang R X. Changes in cholelithiasis in Tianjin in the past 30 years.  Chin Med J (Engl). 1984;  97 (2) 133-135
• 34 Huang Z Q. Characteristic features of cholelithiasis in China. A nationwide survey of 11342 surgical cases 1983–1985.  Zhonghua Wai Ke Za Zhi. 1987;  25 (6) 321-329, 380
• 35 Zhu X, Zhang S, Huang Z. The trend of the gallstone disease in China over the past decade.  Zhonghua Wai Ke Za Zhi. 1995;  33 (11) 652-658
• 36 Nagase M, Tanimura H, Setoyama M, Hikasa Y. Present features of gallstones in Japan. A collective review of 2,144 cases.  Am J Surg. 1978;  135 (6) 788-790
• 37 Nakayama F, Miyake H. Changing state of gallstone disease in Japan. Composition of the stones and treatment of the condition.  Am J Surg. 1970;  120 (6) 794-799
• 38 Leitzmann M F, Giovannucci E L, Rimm E B et al.. The relation of physical activity to risk for symptomatic gallstone disease in men.  Ann Intern Med. 1998;  128 (6) 417-425
• 39 Leitzmann M F, Rimm E B, Willett W C et al.. Recreational physical activity and the risk of cholecystectomy in women.  N Engl J Med. 1999;  341 (11) 777-784
• 40 Misciagna G, Centonze S, Leoci C et al.. Diet, physical activity, and gallstones—a population-based, case-control study in southern Italy.  Am J Clin Nutr. 1999;  69 (1) 120-126
• 41 Tsai C J, Leitzmann M F, Willett W C, Giovannucci E L. Glycemic load, glycemic index, and carbohydrate intake in relation to risk of cholecystectomy in women.  Gastroenterology. 2005;  129 (1) 105-112
• 42 Tsai C J, Leitzmann M F, Willett W C, Giovannucci E L. Dietary carbohydrates and glycaemic load and the incidence of symptomatic gall stone disease in men.  Gut. 2005;  54 (6) 823-828
• 43 Walcher T, Haenle M M, Mason R A, Koenig W, Imhof A, Kratzer W. EMIL Study Group . The effect of alcohol, tobacco and caffeine consumption and vegetarian diet on gallstone prevalence.  Eur J Gastroenterol Hepatol. 2010;  22 (11) 1345-1351
• 44 Wang D Q, Cohen D E, Carey M C. Biliary lipids and cholesterol gallstone disease.  J Lipid Res. 2009;  50 (Suppl) S406-S411
• 45 Rühl C E, Everhart J E. Association of diabetes, serum insulin, and C-peptide with gallbladder disease.  Hepatology. 2000;  31 (2) 299-303
• 46 Stampfer M J, Maclure K M, Colditz G A, Manson J E, Willett W C. Risk of symptomatic gallstones in women with severe obesity.  Am J Clin Nutr. 1992;  55 (3) 652-658
• 47 Portincasa P, Grattagliano I, Palmieri V O, Palasciano G. Current pharmacological treatment of nonalcoholic fatty liver.  Curr Med Chem. 2006;  13 (24) 2889-2900
• 48 Nervi F, Miquel J F, Alvarez M et al.. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population.  J Hepatol. 2006;  45 (2) 299-305
• 49 Loria P, Lonardo A, Lombardini S et al.. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors.  J Gastroenterol Hepatol. 2005;  20 (8) 1176-1184
• 50 Biddinger S B, Haas J T, Yu B B et al.. Hepatic insulin resistance directly promotes formation of cholesterol gallstones.  Nat Med. 2008;  14 (7) 778-782
• 51 Cirillo D J, Wallace R B, Rodabough R J et al.. Effect of estrogen therapy on gallbladder disease.  JAMA. 2005;  293 (3) 330-339
• 52 Körner G. Über die familiäre Häufung der Gallenblasenkrankheiten.  Zeitschrift der menschlichen Vererbungs und Konstitutionslehre. 1937;  20 528-582
• 53 van der Linden W. Genetic factors in gallstone disease.  Clin Gastroenterol. 1973;  2 603-614
• 54 Nakeeb A, Comuzzie A G, Martin L et al.. Gallstones: genetics versus environment.  Ann Surg. 2002;  235 (6) 842-849
• 55 Duggirala R, Mitchell B D, Blangero J, Stern M P. Genetic determinants of variation in gallbladder disease in the Mexican-American population.  Genet Epidemiol. 1999;  16 (2) 191-204
• 56 Puppala S, Dodd G D, Fowler S et al.. A genomewide search finds major susceptibility loci for gallbladder disease on chromosome 1 in Mexican Americans.  Am J Hum Genet. 2006;  78 (3) 377-392
• 57 Lammert F, Wang D Q, Hillebrandt S et al.. Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis.  Hepatology. 2004;  39 (1) 117-128
• 58 Davit-Spraul A, Gendrot C, Parfait B et al.. A58: Sequence variations of ABCB4 gene in the french cohort of hereditary cholestasis and cholelithiasis.  Hepatology. 2010;  52 (Suppl 4) 348A-349A
• 59 Nakken K E, Labori K J, Rødningen O K et al.. ABCB4 sequence variations in young adults with cholesterol gallstone disease.  Liver Int. 2009;  29 (5) 743-747
• 60 Jansen P L, Strautnieks S S, Jacquemin E et al.. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis.  Gastroenterology. 1999;  117 (6) 1370-1379
• 61 van Mil S W, van der Woerd W L, van der Brugge G et al.. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11.  Gastroenterology. 2004;  127 (2) 379-384
• 62 Pullinger C R, Eng C, Salen G et al.. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.  J Clin Invest. 2002;  110 (1) 109-117
• 63 Miyake J H, Duong-Polk X T, Taylor J M et al.. Transgenic expression of cholesterol-7-alpha-hydroxylase prevents atherosclerosis in C57BL/6J mice.  Arterioscler Thromb Vasc Biol. 2002;  22 (1) 121-126
• 64 Lancellotti S, Zaffanello M, Di Leo E, Costa L, Lonardo A, Tarugi P. Pediatric gallstone disease in familial hypobetalipoproteinemia.  J Hepatol. 2005;  43 (1) 188-191
• 65 Schneider H, Sänger P, Hanisch E. In vitro effects of cholecystokinin fragments on human gallbladders. Evidence for an altered CCK-receptor structure in a subgroup of patients with gallstones.  J Hepatol. 1997;  26 (5) 1063-1068
• 66 Miller L J, Holicky E L, Ulrich C D, Wieben E D. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity.  Gastroenterology. 1995;  109 (4) 1375-1380
• 67 Wang D Q, Schmitz F, Kopin A S, Carey M C. Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis.  J Clin Invest. 2004;  114 (4) 521-528
• 68 Buch S, Schafmayer C, Völzke H et al.. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease.  Nat Genet. 2007;  39 (8) 995-999
• 69 Grünhage F, Acalovschi M, Tirziu S et al.. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol.  Hepatology. 2007;  46 (3) 793-801
• 70 Katsika D, Magnusson P, Krawczyk M et al.. Gallstone disease in Swedish twins: risk is associated with ABCG8 D19H genotype.  J Intern Med. 2010;  268 (3) 279-285
• 71 Kuo K K, Shin S J, Chen Z C, Yang Y H, Yang J F, Hsiao P J. Significant association of ABCG5 604Q and ABCG8 D19H polymorphisms with gallstone disease.  Br J Surg. 2008;  95 (8) 1005-1011
• 72 Stender S, Frikke-Schmidt R, Nordestgaard B G, Tybjærg-Hansen A. Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population.  Hepatology. 2011;  53 (2) 640-648
• 73 Siddapuram S P, Mahurkar S, Duvvuru N R et al.. Hepatic cholesterol transporter ABCG8 polymorphisms in gallstone disease in an Indian population.  J Gastroenterol Hepatol. 2010;  25 (6) 1093-1098
• 74 Lyons M A, Wittenburg H. Cholesterol gallstone susceptibility loci: a mouse map, candidate gene evaluation, and guide to human LITH genes.  Gastroenterology. 2006;  131 (6) 1943-1970
• 75 Renner O, Harsch S, Schaeffeler E et al.. A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease.  PLoS ONE. 2009;  4 (10) e7321
• 76 Tsezou A, Tzetis M, Giannatou E et al.. Gilbert syndrome as a predisposing factor for cholelithiasis risk in the Greek adult population.  Genet Test Mol Biomarkers. 2009;  13 (1) 143-146
• 77 Raijmakers M T, Jansen P L, Steegers E A, Peters W H. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene.  J Hepatol. 2000;  33 (3) 348-351
• 78 Duvaldestin P, Mahu J L, Metreau J M, Arondel J, Preaux A M, Berthelot P. Possible role of a defect in hepatic bilirubin glucuronidation in the initiation of cholesterol gallstones.  Gut. 1980;  21 (8) 650-655
• 79 Fevery J, Verwilghen R, Tan T G, De Groote J. Glucuronidation of bilirubin and the occurrence of pigment gallstones in patients with chronic haemolytic diseases.  Eur J Clin Invest. 1980;  10 (3) 219-226
• 80 Ostrow J D. Unconjugated bilirubin and cholesterol gallstone formation.  Hepatology. 1990;  12 (3 Pt 2) 219S-224S
• 81 Strassburg C P. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).  Best Pract Res Clin Gastroenterol. 2010;  24 (5) 555-571
• 82 Angelico M, Gandin C, Canuzzi P et al.. Gallstones in cystic fibrosis: a critical reappraisal.  Hepatology. 1991;  14 (5) 768-775
• 83 Freudenberg F, Broderick A L, Yu B B, Leonard M R, Glickman J N, Carey M C. Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model.  Am J Physiol Gastrointest Liver Physiol. 2008;  294 (6) G1411-G1420
• 84 Freudenberg F, Leonard M R, Liu S A, Glickman J N, Carey M C. Pathophysiological preconditions promoting mixed “black” pigment plus cholesterol gallstones in a DeltaF508 mouse model of cystic fibrosis.  Am J Physiol Gastrointest Liver Physiol. 2010;  299 (1) G205-G214
• 85 Vasavda N, Menzel S, Kondaveeti S et al.. The linear effects of alpha-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease.  Br J Haematol. 2007;  138 (2) 263-270
• 86 Wasmuth H E, Keppeler H, Herrmann U, Schirin-Sokhan R, Barker M, Lammert F. Coinheritance of Gilbert syndrome-associated UGT1A1 mutation increases gallstone risk in cystic fibrosis.  Hepatology. 2006;  43 (4) 738-741
• 87 European Association for the Study of the Liver . EASL Clinical Practice Guidelines: management of cholestatic liver diseases.  J Hepatol. 2009;  51 (2) 237-267
• 88 Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene.  Orphanet J Rare Dis. 2007;  2 29
• 89 Schwertner H A, Vítek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin.  Atherosclerosis. 2008;  198 (1) 1-11
• 90 Park J H, Wacholder S, Gail M H et al.. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries.  Nat Genet. 2010;  42 (7) 570-575
• 91 de los Campos G, Gianola D, Allison D B. Predicting genetic predisposition in humans: the promise of whole-genome markers.  Nat Rev Genet. 2010;  11 (12) 880-886
• 92 Bansal V, Libiger O, Torkamani A, Schork N J. Statistical analysis strategies for association studies involving rare variants.  Nat Rev Genet. 2010;  11 (11) 773-785
• 93 Plomin R, Haworth C M, Davis O S. Common disorders are quantitative traits.  Nat Rev Genet. 2009;  10 (12) 872-878
• 94 Paumgartner G, Greenberger N. Diseases of the gallbladder and bile ducts. In: Longo D, Faucia , eds. Harrison's Gastroenterology and Hepatology. 1st eds. New York, NY: McGraw-Hill Professional; 2010: 439-457
• 95 Di Ciaula A, Wang D Q, Wang H H, Bonfrate L, Portincasa P. Targets for current pharmacologic therapy in cholesterol gallstone disease.  Gastroenterol Clin North Am. 2010;  39 (2) 245-264
• 96 Shiffman M L, Sugerman H J, Kellum J M, Brewer W H, Moore E W. Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity.  Am J Gastroenterol. 1991;  86 (8) 1000-1005
• 97 Shiffman M L, Kaplan G D, Brinkman-Kaplan V, Vickers F F. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program.  Ann Intern Med. 1995;  122 (12) 899-905
• 98 Sugerman H J, Brewer W H, Shiffman M L et al.. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss.  Am J Surg. 1995;  169 (1) 91-96, discussion 96–97
• 99 Vítek L, Muchová L, Zelenka J, Zadinová M, Malina J. The effect of zinc salts on serum bilirubin levels in hyperbilirubinemic rats.  J Pediatr Gastroenterol Nutr. 2005;  40 (2) 135-140
• 100 Hafkamp A M, Nelisse-Haak R, Sinaasappel M, Oude Elferink R P, Verkade H J. Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial.  Pediatr Res. 2007;  62 (6) 725-730
• 101 Hofmann A F, Zakko S F, Lira M et al.. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.  Hepatology. 2005;  42 (6) 1391-1398
• 102 Broderick A L, Wittenburg H, Lyons M A, Stechell K DR, Hofmann A F, Carey M C. Cystic fibrosis transmembrane conductance regulator gene mutations cause “black” pigment gallstone formation: new insights from mouse models and implications for therapeutic interventions in cystic fibrosis. In:, Adler G, Fuchs M, Stange E F, eds. Gallstone Pathogenesis and Treatment. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2004: 24-27
• 103 Venneman N G, Buskens E, Besselink M G et al.. Small gallstones are associated with increased risk of acute pancreatitis: potential benefits of prophylactic cholecystectomy?.  Am J Gastroenterol. 2005;  100 (11) 2540-2550
• 104 Fracchia M, Pellegrino S, Secreto P et al.. Biliary lipid composition in cholesterol microlithiasis.  Gut. 2001;  48 (5) 702-706
• 105 Moschetta A, Bookout A L, Mangelsdorf D J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model.  Nat Med. 2004;  10 (12) 1352-1358
• 106 Wang H H, Portincasa P, Mendez-Sanchez N, Uribe M, Wang D Q. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.  Gastroenterology. 2008;  134 (7) 2101-2110
• 107 Zúñiga S, Molina H, Azocar L et al.. Ezetimibe prevents cholesterol gallstone formation in mice.  Liver Int. 2008;  28 (7) 935-947
• 108 Grünhage F, Lammert F. Gallstone disease. Pathogenesis of gallstones: A genetic perspective.  Best Pract Res Clin Gastroenterol. 2006;  20 (6) 997-1015
• 109 Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis.  Gastroenterology. 2001;  120 (6) 1459-1467
• 110 Lucena J F, Herrero J I, Quiroga J et al.. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis.  Gastroenterology. 2003;  124 (4) 1037-1042
• 111 Figge A, Lammert F, Paigen B et al.. Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis.  J Biol Chem. 2004;  279 (4) 2790-2799
• 112 Henkel A, Wei Z, Cohen D E, Green R M. Mice overexpressing hepatic Abcb11 rapidly develop cholesterol gallstones.  Mamm Genome. 2005;  16 (12) 903-908
• 113 Yu L, Li-Hawkins J, Hammer R E et al.. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol.  J Clin Invest. 2002;  110 (5) 671-680
• 114 Xu H L, Cheng J R, Andreotti G et al.. Cholesterol metabolism gene polymorphisms and the risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China.  Carcinogenesis. 2011;  32 (1) 58-62
• 115 Klass D M, Lauer N, Hay B, Kratzer W, Fuchs M. EMIL Study Group . Arg64 variant of the beta3-adrenergic receptor is associated with gallstone formation.  Am J Gastroenterol. 2007;  102 (11) 2482-2487
• 116 Dixit M, Choudhuri G, Saxena R, Mittal B. Association of apolipoprotein A1-C3 gene cluster polymorphisms with gallstone disease.  Can J Gastroenterol. 2007;  21 (9) 569-575
• 117 Yao Y G, Qiu X, Ma M K, Pu D S, Xiao L J. Apolipoprotein AI-CIII-AIV gene cluster polymorphisms in relation to cholesterol gallstone.  J Dig Dis. 2007;  8 (1) 52-57
• 118 Han T, Jiang Z, Suo G, Zhang S. Apolipoprotein B-100 gene Xba I polymorphism and cholesterol gallstone disease.  Clin Genet. 2000;  57 (4) 304-308
• 119 Jiang Z Y, Han T Q, Suo G J et al.. Polymorphisms at cholesterol 7alpha-hydroxylase, apolipoproteins B and E and low density lipoprotein receptor genes in patients with gallbladder stone disease.  World J Gastroenterol. 2004;  10 (10) 1508-1512
• 120 Kurzawski M, Juzyszyn Z, Modrzejewski A et al.. Apolipoprotein B (APOB) gene polymorphism in patients with gallbladder disease.  Arch Med Res. 2007;  38 (3) 360-363
• 121 Lancellotti S, Zaffanello M, Di Leo E, Costa L, Lonardo A, Tarugi P. Pediatric gallstone disease in familial hypobetalipoproteinemia.  J Hepatol. 2005;  43 (1) 188-191
• 122 Wang H H, Wang D Q. Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine.  Hepatology. 2005;  42 (4) 894-904
• 123 Liu F L, Lu W B, Niu W X. XbaI polymorphisms of apolipoprotein B gene: another risk factor of gallstone formation after radical gastrectomy.  World J Gastroenterol. 2010;  16 (20) 2549-2553
• 124 Dixit M, Choudhuri G, Mittal B. Association of APOE-C1 gene cluster polymorphisms with gallstone disease.  Dig Liver Dis. 2006;  38 (6) 397-403
• 125 Kitsiou-Tzeli S, Giannatou E, Spanos I et al.. Steroid hormones polymorphisms and cholelithiasis in Greek population.  Liver Int. 2007;  27 (1) 61-68
• 126 Srivastava A, Pandey S N, Dixit M, Choudhuri G, Mittal B. Cholecystokinin receptor A gene polymorphism in gallstone disease and gallbladder cancer.  J Gastroenterol Hepatol. 2008;  23 (6) 970-975
• 127 Miyasaka K, Takata Y, Funakoshi A. Association of cholecystokinin A receptor gene polymorphism with cholelithiasis and the molecular mechanisms of this polymorphism.  J Gastroenterol. 2002;  37 (Suppl 14) 102-106
• 128 Juvonen T, Savolainen M J, Kairaluoma M I, Lajunen L H, Humphries S E, Kesäniemi Y A. Polymorphisms at the apoB, apoA-I, and cholesteryl ester transfer protein gene loci in patients with gallbladder disease.  J Lipid Res. 1995;  36 (4) 804-812
• 129 Kovacs P, Kress R, Rocha J et al.. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans.  J Hepatol. 2008;  48 (1) 116-124
• 130 Dixit M, Choudhuri G, Keshri L J, Mittal B. Association of low density lipoprotein receptor related protein-associated protein (LRPAP1) gene insertion/deletion polymorphism with gallstone disease.  J Gastroenterol Hepatol. 2006;  21 (5) 847-849
• 131 Srivastava A, Srivastava A, Srivastava N, Choudhuri G, Mittal B. Organic anion transporter 1B1 (SLCO1B1) polymorphism and gallstone formation: High incidence of Exon4 CA genotype in female patients in North India.  Hepatol Res. 2011;  41 (1) 71-78
• 132 Tamary H, Aviner S, Freud E et al.. High incidence of early cholelithiasis detected by ultrasonography in children and young adults with hereditary spherocytosis.  J Pediatr Hematol Oncol. 2003;  25 (12) 952-954
• 133 Trotman B W, Bernstein S E, Bove K E, Wirt G D. Studies on the pathogenesis of pigment gallstones in hemolytic anemia: description and characteristics of a mouse model.  J Clin Invest. 1980;  65 (6) 1301-1308
• 134 Schröter W, Eber S W, Bardosi A, Gahr M, Gabriel M, Sitzmann F C. Generalised glucosephosphate isomerase (GPI) deficiency causing haemolytic anaemia, neuromuscular symptoms and impairment of granulocytic function: a new syndrome due to a new stable GPI variant with diminished specific activity (GPI Homburg).  Eur J Pediatr. 1985;  144 (4) 301-305
• 135 Borgna-Pignatti C, Rigon F, Merlo L et al.. Thalassemia minor, the Gilbert mutation, and the risk of gallstones.  Haematologica. 2003;  88 (10) 1106-1109
• 136 Walker T M, Hambleton I R, Serjeant G R. Gallstones in sickle cell disease: observations from The Jamaican Cohort study.  J Pediatr. 2000;  136 (1) 80-85
• 137 Hsu L, Diwan B, Ward J M, Noguchi C T. Pathology of “Berkeley” sickle-cell mice includes gallstones and priapism.  Blood. 2006;  107 (8) 3414-3415
• 138 Au W Y, Cheung W C, Hu W H et al.. Hyperbilirubinemia and cholelithiasis in Chinese patients with hemoglobin H disease.  Ann Hematol. 2005;  84 (10) 671-674
• 139 Au W Y, Cheung W C, Chan G C, Ha S Y, Khong P L, Ma E S. Risk factors for hyperbilirubinemia and gallstones in Chinese patients with b thalassemia syndrome.  Haematologica. 2003;  88 (2) 220-222
• 140 Galanello R, Piras S, Barella S et al.. Cholelithiasis and Gilbert's syndrome in homozygous beta-thalassaemia.  Br J Haematol. 2001;  115 (4) 926-928
• 141 del Giudice E M, Perrotta S, Nobili B, Specchia C, d'Urzo G, Iolascon A. Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis.  Blood. 1999;  94 (7) 2259-2262
• 142 Haverfield E V, McKenzie C A, Forrester T et al.. UGT1A1 variation and gallstone formation in sickle cell disease.  Blood. 2005;  105 (3) 968-972
• 143 Kitsiou-Tzeli S, Kanavakis E, Tzetis M, Kavazarakis E, Galla A, Tsezou A. Gilbert's syndrome as a predisposing factor for idiopathic cholelithiasis in children.  Haematologica. 2003;  88 (10) 1193-1194
• 144 Chaar V, Kéclard L, Diara J P et al.. Association of UGT1A1 polymorphism with prevalence and age at onset of cholelithiasis in sickle cell anemia.  Haematologica. 2005;  90 (2) 188-199
• 145 Premawardhena A, Fisher C A, Fathiu F et al.. Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassaemia.  Lancet. 2001;  357 (9272) 1945-1946
• 146 Fertrin K Y, Melo M B, Assis A M, Saad S T, Costa F F. UDP-glucuronosyltransferase 1 gene promoter polymorphism is associated with increased serum bilirubin levels and cholecystectomy in patients with sickle cell anemia.  Clin Genet. 2003;  64 (2) 160-162
• 147 Passon R G, Howard T A, Zimmerman S A, Schultz W H, Ware R E. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia.  J Pediatr Hematol Oncol. 2001;  23 (7) 448-451
• 148 Chu C H, Yang A M, Kao J H, Liu C Y, Chang W H, Yang W S. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism is associated with choledocholithiasis in Taiwanese patients.  J Gastroenterol Hepatol. 2009;  24 (9) 1559-1561
• 149 Park S K, Andreotti G, Sakoda L C et al.. Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China.  Carcinogenesis. 2009;  30 (4) 606-614
• 150 Hsing A W, Sakoda L C, Rashid A et al.. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China.  Cancer Res. 2008;  68 (15) 6442-6452
• 151 Dixit M, Choudhuri G, Mittal B. Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: A case-control study.  Hepatol Res. 2006;  36 (1) 61-69